Market closedNon-fractional
EyePoint Pharmaceuticals/EYPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Ticker
EYPT
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Watertown, United States
Employees
121
Website
eyepointpharma.com
EYPT Metrics
BasicAdvanced
$493M
Market cap
-
P/E ratio
-$1.85
EPS
1.72
Beta
-
Dividend rate
Price and volume
Market cap
$493M
Beta
1.72
Financial strength
Current ratio
5.077
Quick ratio
4.832
Long term debt to equity
1.85
Total debt to equity
2.323
Interest coverage (TTM)
-196.86%
Management effectiveness
Return on assets (TTM)
-22.12%
Return on equity (TTM)
-48.07%
Valuation
Price to revenue (TTM)
8.087
Price to book
1.89
Price to tangible book (TTM)
1.89
Price to free cash flow (TTM)
-24.289
Growth
Revenue change (TTM)
25.70%
Earnings per share change (TTM)
-32.67%
3-year revenue growth (CAGR)
13.43%
3-year earnings per share growth (CAGR)
-12.54%
What the Analysts think about EYPT
Analyst Ratings
Majority rating from 11 analysts.
EYPT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12M
-17.14%
Net income
-$29M
108.57%
Profit margin
-251.72%
151.72%
EYPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.61
-$0.33
-$0.33
-$0.55
-
Expected
$0.60
-$0.51
-$0.49
-$0.42
-$0.52
Surprise
-201.88%
-35.65%
-32.11%
32.21%
-
EYPT News
AllArticlesVideos
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
GlobeNewsWire·1 month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for EyePoint Pharmaceuticals stock?
EyePoint Pharmaceuticals (EYPT) has a market cap of $493M as of July 27, 2024.
What is the P/E ratio for EyePoint Pharmaceuticals stock?
The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of July 27, 2024.
Does EyePoint Pharmaceuticals stock pay dividends?
No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next EyePoint Pharmaceuticals dividend payment date?
EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.
What is the beta indicator for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.72. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell EyePoint Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.